Cargando…

Leishmania donovani Growth Inhibitors from Pathogen Box Compounds of Medicine for Malaria Venture

INTRODUCTION: Leishmaniasis is a collective term used to describe various pathological conditions caused by an obligate intracellular protozoan of the genus Leishmania. It is one of the neglected diseases and has been given minimal attention by drug discovery and development stakeholders to narrow t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tadele, Markos, Abay, Solomon M, Makonnen, Eyasu, Hailu, Asrat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7130106/ https://www.ncbi.nlm.nih.gov/pubmed/32280200 http://dx.doi.org/10.2147/DDDT.S244903

Ejemplares similares

In vitro growth inhibitory activity of Medicines for Malaria Venture pathogen box compounds against Leishmania aethiopica
por: Tadele, Markos, et al.
Publicado: (2021)

In vitro Anti-Leishmanial Activities of Methanol Extract of Brucea antidysenterica J.F. Mill Seeds and Its Solvent Fractions
por: Ketema, Tasisa, et al.
Publicado: (2023)

Novel Antifungal Compounds Discovered in Medicines for Malaria Venture’s Malaria Box
por: Jung, Eric H., et al.
Publicado: (2018)

Identification of Anti-staphylococcal and Anti-biofilm Compounds by Repurposing the Medicines for Malaria Venture Pathogen Box
por: Bhandari, Vasundhra, et al.
Publicado: (2018)

Screening the Medicines for Malaria Venture Pathogen Box against piroplasm parasites
por: Nugraha, Arifin Budiman, et al.
Publicado: (2019)

Elucidating the possible mechanism of action of some pathogen box compounds against Leishmania donovani
por: Amlabu, Wandayi Emmanuel, et al.
Publicado: (2020)

Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box against Intracellular Leishmania major Amastigotes
por: Khraiwesh, Mozna, et al.
Publicado: (2016)

Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever
por: Nyagwange, James, et al.
Publicado: (2019)

Repositionable Compounds with Antifungal Activity against Multidrug Resistant Candida auris Identified in the Medicines for Malaria Venture’s Pathogen Box
por: Wall, Gina, et al.
Publicado: (2019)

PfATP4 inhibitors in the Medicines for Malaria Venture Malaria Box and Pathogen Box block the schizont-to-ring transition by inhibiting egress rather than invasion
por: Barnes, Claudia B. G., et al.
Publicado: (2022)

Polymorphism in the HASPB Repeat Region of East African Leishmania donovani Strains
por: Zackay, Arie, et al.
Publicado: (2013)

The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites
por: Looker, Oliver, et al.
Publicado: (2022)

Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery
por: Duffy, Sandra, et al.
Publicado: (2017)

Medicines for Malaria Venture COVID Box: a source for repurposing drugs with antifungal activity against human pathogenic fungi
por: Almeida-Paes, Rodrigo, et al.
Publicado: (2021)

Temporal and Wash-Out Studies Identify Medicines for Malaria Venture Pathogen Box Compounds with Fast-Acting Activity against Both Trypanosoma cruzi and Trypanosoma brucei
por: Sykes, Melissa L., et al.
Publicado: (2022)

Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni
por: Pasche, Valérian, et al.
Publicado: (2018)

Inference of Population Structure of Leishmania donovani Strains Isolated from Different Ethiopian Visceral Leishmaniasis Endemic Areas
por: Gelanew, Tesfaye, et al.
Publicado: (2010)

Genome wide comparison of Ethiopian Leishmania donovani strains reveals differences potentially related to parasite survival
por: Zackay, Arie, et al.
Publicado: (2018)

Prevalence and Determinants of Schistosoma mansoni Infection among Pre-School Age Children in Southern Ethiopia
por: Tadele, Tafese, et al.
Publicado: (2023)

A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box
por: Jumani, R. S., et al.
Publicado: (2018)

Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa
por: Macho, Markéta, et al.
Publicado: (2022)

Genomic analysis of natural intra-specific hybrids among Ethiopian isolates of Leishmania donovani
por: Cotton, James A., et al.
Publicado: (2020)

In vitro activity and mode of action of phenolic compounds on Leishmania donovani
por: Antwi, Christine Achiaa, et al.
Publicado: (2019)

Compounds from the Medicines for Malaria Venture Box Inhibit In Vitro Growth of Babesia divergens, a Blood-Borne Parasite of Veterinary and Zoonotic Importance
por: Rizk, Mohamed Abdo, et al.
Publicado: (2021)

Analysis of genetic polymorphisms and tropism in East African Leishmania donovani by Amplified Fragment Length Polymorphism and kDNA minicircle sequencing
por: Jaber, Hanan T., et al.
Publicado: (2018)

Screening the Medicines for Malaria Venture "Malaria Box" against the Plasmodium falciparum Aminopeptidases, M1, M17 and M18
por: Paiardini, Alessandro, et al.
Publicado: (2015)

Sero-prevalence of Leishmania donovani infection in labour migrants and entomological risk factors in extra-domestic habitats of Kafta-Humera lowlands - kala-azar endemic areas in the northwest Ethiopia
por: Lemma, Wossenseged, et al.
Publicado: (2015)

Multilocus sequence and microsatellite identification of intra-specific hybrids and ancestor-like donors among natural Ethiopian isolates of Leishmania donovani
por: Gelanew, Tesfaye, et al.
Publicado: (2014)

LEISHMANIA DONOVANI IN THE PERIPHERAL BLOOD
por: Young, Charles W., et al.
Publicado: (1923)

Minimally invasive microbiopsies: a novel sampling method for identifying asymptomatic, potentially infectious carriers of Leishmania donovani
por: Kirstein, Oscar David, et al.
Publicado: (2017)

Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules
por: Subramanian, Gowtham, et al.
Publicado: (2018)

Short-term impact of celebrating the international clinical trial day: experience from Ethiopia
por: Fekadu, Abebaw, et al.
Publicado: (2017)

Sergentomyia schwetzi is not a competent vector for Leishmania donovani and other Leishmania species pathogenic to humans
por: Sadlova, Jovana, et al.
Publicado: (2013)

Metabolic Reprogramming during Purine Stress in the Protozoan Pathogen Leishmania donovani
por: Martin, Jessica L., et al.
Publicado: (2014)

Phlebotomus orientalis Sand Flies from Two Geographically Distant Ethiopian Localities: Biology, Genetic Analyses and Susceptibility to Leishmania donovani
por: Seblova, Veronika, et al.
Publicado: (2013)

Proteomic analysis of the secretome of Leishmania donovani
por: Silverman, J Maxwell, et al.
Publicado: (2008)

Surface antigens of Leishmania donovani promastigotes
Publicado: (1983)

Vaccine Development Against Leishmania donovani
por: Das, Amrita, et al.
Publicado: (2012)

Leishmania donovani bodies in bone marrow
por: Ali, Natasha, et al.
Publicado: (2014)

Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosine
por: Tegazzini, Diana, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_63ocads0petc8kvtq7pg6kuph1